Bicara Therapeutics (BCAX) Q2 2026 earnings summary

Executive summary

• Multiple strategic leadership transitions announced, including new CEO, COO, CFO, and Chief Legal Officer, effective January 2027, to support commercialization and growth.

• Focus remains on advancing FICERA (ficerafusp alfa), a bifunctional EGFR/TGF-β inhibitor, through pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer.

• FICERA's pivotal trial showed nearly doubled three-year overall survival versus standard of care, with consistent safety profile.

• Company is preparing for potential commercialization, expanding operational and commercial capabilities.

• No commercial revenue to date; operations funded by equity offerings, including a $161.8M raise in February 2026.

Financial highlights

• Q2 2026 operating expenses rose to $60.0M from $32.0M in Q2 2025, mainly due to higher R&D and personnel costs.

• Research & development expenses were $45.8M in Q2 2026; G&A expenses increased to $14.2M.

• Net loss for Q2 2026 was $55.4M, up from $27.4M in Q2 2025; six-month net loss was $111.6M.

• Cash, cash equivalents, and marketable securities totaled $497.3M as of June 30, 2026.

• Cash runway expected to fund operations into the first half of 2029.

Outlook and guidance

• Substantial enrollment of pivotal FORTIFI-HN01 trial expected by year-end 2026, with interim topline results anticipated mid-2027.

• FORTIFI-FLEX alternate dosing study initiated, with results expected in time for potential U.S. accelerated approval.

• Strategic investments planned to maximize long-term value and support commercialization.

• Data from Phase 1b expansion cohort in mCRC expected in the second half of 2026.